First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial

Published:2024-05 Issue:5 Volume:11 Page:e336-e344
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Tian Xiao-Peng,Cai Jun,Xia Yi,Zhang Yu-Chen,Wang Liang,Liu Pan-Pan,Huang Hui-Qiang,Li Ya-Jun,Zhou Hui,Li Zhi-Ming,Yang Jing,Wei Li-Qiang,Zou Qi-Hua,Huang Ying,Li Jun,Ling Li,Zhong Wen-Long,Cai Qing-Qing

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference31 articles.

1. Review on natural killer/T-cell lymphoma;He;Hematol Oncol,2023

2. Extranodal natural killer/T-cell lymphoma: an overview on pathology and clinical management;Tse;Semin Hematol,2022

3. Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma;Tian;Cell Rep Med,2023

4. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study;Yamaguchi;J Clin Oncol,2011

5. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma;Wang;Oncotarget,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphoma;Med;2024-07

2. First-line immunochemotherapy for extranodal natural killer/T cell lymphoma;The Lancet Haematology;2024-05